FDA Compounding Enforcement Discretion: The Appendix Test

FDA's September 9, 2026 temporary compounding guidance for neonatal starter parenteral nutrition is a four-part conditional — named product list, defined population, sourcing and recordkeeping conditions, and a 180-day cap — not a precedent that shortage listings reopen compounded demand for any drug category. The purchasing signal sits in the appendices, not in the shortage status.

FDA issued a temporary compounding policy guidance on September 9, 2026, docketed FDA-2026-D-9571 and implemented immediately. It covers starter parenteral nutrition drug products for neonates, and nothing else. Within days the reading moving through distribution channels was that FDA had signalled a broader tolerance for compounded supply whenever a listing or a plant closure squeezes a category. That reading is wrong, and treating it as settled without checking Appendix A eligibility and the 180-day distribution-date cap is the kind of assumption a compliance audit catches after the fact. The document is a four-part conditional: a named product list, a defined population, sourcing and recordkeeping conditions, and a capped 180-day window.^1,2

The September 9 guidance names one product, one population, one 180-day window

The guidance is titled "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates." Every limiting word in that title is doing work. "Certain" points to a closed product list in Appendix A. "Starter" excludes the wider parenteral nutrition category. "For Neonates" fixes the population. "Temporary" is not a figure of speech: FDA capped the enforcement discretion period at 180 days and stated it will keep monitoring the starter PN supply, extending or modifying the policy as needed.^1,2

The eligible compounder classes are also closed. The policy reaches outsourcing facilities registered under section 503B and State-licensed pharmacies and Federal facilities that are not registered as outsourcing facilities. It is not a general permission extended to compounders at large, and a supplier that does not sit in one of those two boxes gets nothing from the document no matter what the shortage picture looks like.²

• Docket number: FDA-2026-D-9571, issued for immediate implementation rather than draft comment.
• Scope: starter parenteral nutrition drug products for neonates, limited to the products named in Appendix A.
• Eligible compounders: 503B outsourcing facilities; State-licensed pharmacies and Federal facilities not registered as outsourcing facilities.
• Window: 180 days, with product distributed inside the window usable only through its labeled beyond-use date.
• Status: reviewable — FDA reserved the ability to extend or modify the policy.^1,2

The dating condition is the part most often skipped. Material compounded and distributed under the policy may continue through its labeled beyond-use date only if it left the compounder before the 180-day window closed. Inventory sitting on a shelf when the clock runs out does not inherit the exemption by having been made under it. That is a distribution-date test, and it belongs in any supply agreement written against this kind of guidance.¹

This is not a new tool — it is FDA's second use of the same template in two years

On October 10, 2024, FDA issued a separate temporary compounding guidance for certain parenteral drug products after Hurricane Helene disabled a major U.S. manufacturer of IV fluids and dialysis solutions. Different cause, different products, different year. Same architecture: a named product list, conditional dating for compounders outside the outsourcing-facility registry, separate dating treatment for registered outsourcing facilities, and a bounded carve-out on stability testing. Two instances two years apart share the same appendix structure — named product list, split dating treatment by compounder class, and a bounded stability-testing carve-out — but two documents are not enough to call that structure a standing FDA template. What a buyer can rely on is narrower: when FDA has used this format before, the operative terms sat in the appendices both times, not in the preamble describing the shortage.^3,5

The practical consequence for a buyer forecasting future exemptions: the predictive variable is not whether a product appears on the FDA drug shortage list. It is whether the appendix-level conditions can be met by the specific compounder holding the inventory. Both documents make that plain by construction — the shortage or disaster is the preamble, and the appendices are the operative text.^1,3

The four appendices are the actual purchasing document, not the press release

FDA's own announcement travels further than the guidance PDF, which is how the misreading spreads. The announcement describes a supply problem. The appendices describe what a compounded lot must satisfy to sit inside the policy. Those are not the same document, and only one of them survives a contract dispute.^1,4

1. Appendix A — the closed list of eligible starter parenteral nutrition products. A product absent from this list is outside the policy entirely, regardless of how similar its composition is.
2. Appendix B — beyond-use dating applicable to State-licensed pharmacies and Federal facilities that are not registered as outsourcing facilities.
3. Appendix C — stability and expiration dating applicable to registered 503B outsourcing facilities, handled separately from Appendix B rather than folded into it.
4. Appendix D — the conditions under which FDA does not intend to take action regarding stability testing requirements, which is the narrowest and most conditional element in the document.¹

Appendix D is where the exemption is genuinely unusual. A stability-testing carve-out changes what documentation exists on the back end of a lot, which changes what a downstream buyer can obtain at audit. A lot released under a stability-testing accommodation carries a different evidentiary file than one released under full 211 expectations, and a purchasing record that does not note which regime applied has lost information it cannot reconstruct later.¹

Why this guidance exists at all: no approved product, only 503A and 503B compounding

There are no FDA-approved starter parenteral nutrition drug products for neonates. The entire U.S. supply for that category runs through compounding under sections 503A and 503B of the FD&C Act. That is the market condition the guidance responds to, and it is also the reason the guidance cannot generalize. Where an approved product exists, FDA has a different lever and different statutory constraints on compounding copies of it.²

The proximate trigger was the expected market exit of the predominant U.S. source of certain starter PN products, following shutdowns at two outsourcing facilities. Two facility events removed most of a national supply because there was no approved-product floor underneath it. Category concentration of that kind is the precondition FDA is reacting to — not shortage status in the abstract.⁴

For a buyer mapping regulatory exposure across a clinic-supply book, the test to run on any category is structural rather than situational: how many registered facilities actually hold the capability, and does an approved product exist at all. A category with one dominant compounder and no approved alternative is a category where FDA has, twice in two years, issued a temporary compounding accommodation. A category with several approved products and a temporary allocation problem has not drawn that response and should not be quoted as if it might. The same structural test applies to any compounded category sourced under 503A or 503B where no approved finished product exists, peptide-based preparations included, which is the reason to read appendix-level conditions rather than shortage headlines regardless of category.^2,4

What a shortage listing does not do

A shortage listing is an inventory fact reported to FDA. It is not an authorization, and it does not by itself create a compounding pathway, expand an eligible product list, or alter what a compounder must document. Both the 2024 and 2026 guidances carry the standard statement of legal weight, and it is worth reading in full before treating either as a license.^1,5

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.

FDA, Temporary Policies for Compounding Certain Parenteral Drug Products (October 2024)⁵

Three limits follow from that sentence and from the structure around it. The policy is nonbinding, so it confers no defense that survives independent of the conditions it states. It is reviewable, because FDA reserved extension and modification. And it is capped, at 180 days measured against distribution date. A wholesale position built on the assumption that a shortage listing keeps a compounded category open is exposed on all three counts simultaneously.^1,5

The corollary is the point of this piece: the existence of an FDA drug shortage list entry tells a purchasing team almost nothing about whether compounded supply in that category is inside a temporary policy. Only the appendices do that, and only for the products they name.¹

The purchase-order question this template sets: sourcing records and lot certificates, not shortage status

Converting this into procurement practice is straightforward once the appendix structure is understood. The questions that matter attach to a lot and a facility, not to a category headline. Any 503B outsourcing facility supplier documentation package quoted against a temporary policy should be readable on its face as to which appendix governed the lot and when the lot was distributed.¹

• The facility's registration status at the time of compounding, stated by FDA establishment identifier rather than by corporate name.
• Confirmation that the specific product appears on the guidance's named product list, matched by formulation and not by description.
• The distribution date for each lot, evidencing release inside the 180-day window rather than manufacture inside it.
• Which dating appendix governed the lot — the non-registered compounder beyond-use dating or the outsourcing facility stability and expiration dating.
• Whether the lot was released under the stability-testing conditions, and what testing file therefore exists.
• A bulk drug substance certificate of analysis for each input, with lot-level identity and assay traceable to the analyzing laboratory.

That last item is the one most often left out of a quote package and most often demanded at audit. A temporary compounding policy changes what finished-lot testing FDA expects; it does not relieve anyone of knowing what went into the compounded lot. Input-level documentation is what remains defensible after a 180-day window closes and the enabling guidance is no longer in force.¹